Cancer Research

MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment

11/03/2022

Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries Excerpt from the Press Release: MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ — MyOme, a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score…

Read More

Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

11/02/2022

OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines, today announced…

Read More

Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

11/02/2022

– MCLA-129 observed to be well tolerated with a favorable safety profile – Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels​ – Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enrolling – Investor call to discuss a MCLA-129 program update on October 26 at 13:30…

Read More

Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer-Related Lymphedema

11/01/2022

L-Dex Found to be a Cost Effective, Reproducible, and Practical Method to Monitor Breast Cancer Patients for Early Signs of Lymphedema Excerpt from the Press Release: CARLSBAD, Calif., Oct. 26, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD) is pleased to announce publication of a systematic literature review showing that early detection and intervention of breast…

Read More

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom’s Macroglobulinemia

10/31/2022

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman Excerpt from the Press Release: WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential…

Read More

Verastem Oncology Appoints Anil Kapur to Board of Directors

10/27/2022

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022. Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. “Anil’s deep…

Read More

BMF-219 Enters the Clinic for KRAS Solid Tumors

10/20/2022

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. Biomea Fusion will now initiate a Phase I/Ib clinical trial (COVALENT-102) of BMF-219 as a monotherapy in patients who have unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC) or pancreatic…

Read More

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Update

10/18/2022

FDA Meeting Planned for Q4 to Discuss Regulatory Path Forward Based on Encouraging Results to Date in Ongoing RAMP 201 Trial in LGSOC Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase RAMP Trials with VS-6766 Combinations in KRAS…

Read More

Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response

10/18/2022

AMP-protein-based vaccines administered intranasally to mice and nonhuman primates (NHPs) were transported across the epithelial lining to the nasal-associated lymphoid tissue (NALT) and persisted in the nasal mucosa eliciting immune responses at both local and distal mucosal sites Intranasal immunization with AMP-conjugated HIV Env gp120 or SARS-CoV-2 receptor binding domain (RBD) proteins elicited 100- to…

Read More

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

10/17/2022

Excerpt from the Press Release: CARLSBAD, Calif. and BRISBANE, Australia, Oct. 4, 2022 /PRNewswire/ — ImpediMed Limited (ASX.IPD) is pleased to announce the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an initial roll out of five (5) SOZO® units to establish lymphedema screening services…

Read More